We are a seasoned and passionate team, committed to developing high impact and life changing therapies which heal the heart.

Investor Resources


Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company’s lead small molecule drug candidate, CardiolRx™ (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease.



It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure.
Learn more

Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration (“US FDA”) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx™ in two diseases affecting the heart: (i) a Phase II multi-center open-label pilot study in recurrent pericarditis (the MAvERIC-Pilot study; NCT05494788), an inflammatory disease of the pericardium which is associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, and results in physical limitations, reduced quality of life, emergency department visits, and hospitalizations; and (ii) a Phase II multi-national, randomized, double-blind, placebo-controlled trial (the ARCHER trial; NCT05180240) in acute myocarditis, an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in people less than 35 years of age. The US FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, which includes recurrent pericarditis.
Learn more

Cardiol is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure – a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding $30 billion annually.
Learn more


David Elsley, MBA
David Elsley, MBA President and Chief Executive Officer
Andrew Hamer, MBChB
Andrew Hamer, MBChB Chief Medical Officer and Head of Research & Development
Chris Waddick, MBA, CPA, CMA
Chris Waddick, MBA, CPA, CMA Chief Financial Officer
Bernard Lim, MIET, CEng (UK)
Bernard Lim, MIET, CEng (UK) Chief Operating Officer
Andrea B. Parker, MSc, PhD
Andrea B. Parker, MSc, PhD Senior Director of Clinical Operations
John A. Geddes, MBA
John A. Geddes, MBA Vice President, Corporate Development
Anne Tomalin, BA, BSc, RAC
Anne Tomalin, BA, BSc, RAC Director of Regulatory and Quality
Blagoya Ristevski, BSc, CHE
Blagoya Ristevski, BSc, CHE Director of Chemical Engineering and Manufacturing
Guillermo Torre-Amione, MD, PhD
Guillermo Torre-Amione, MD, PhD Chairman
David Elsley, MBA
David Elsley, MBA President and Chief Executive Officer
Chris Waddick, MBA, CPA, CMA
Chris Waddick, MBA, CPA, CMA Chief Financial Officer
Jennifer M. Chao, BA
Jennifer M. Chao, BA Director
Teri Loxam, MBA
Teri Loxam, MBA Director
Peter Pekos, BSc, MSc
Peter Pekos, BSc, MSc Director
Colin G. Stott, BSc (Hons)
Colin G. Stott, BSc (Hons) Director
Michael J. Willner, Esq.
Michael J. Willner, Esq. Director
Paul M. Ridker, MD, MPH
Paul M. Ridker, MD, MPH
Bruce McManus, PhD, MD
Bruce McManus, PhD, MD
Joseph A. Hill, MD, PhD
Joseph A. Hill, MD, PhD
Allan Klein, MD, CM
Allan Klein, MD, CM Pericarditis Advisor Study Chair
Paul Cremer, MD
Paul Cremer, MD Pericarditis Advisor
Antonio Abbate, MD, PhD
Antonio Abbate, MD, PhD Pericarditis Advisor
Allen Luis, MBBS, PhD
Allen Luis, MBBS, PhD Pericarditis Advisor
Stefano Toldo, PhD
Stefano Toldo, PhD Pericarditis Advisor
Stephen Nicholls, MBBS, PhD
Stephen Nicholls, MBBS, PhD Pericarditis Advisor
Dennis M. McNamara, MD
Dennis M. McNamara, MD ARCHER Steering Committee Chair
Leslie T. Cooper, Jr., MD
Leslie T. Cooper, Jr., MD ARCHER Steering Committee Co-Chair
Arvind Bhimaraj, MD
Arvind Bhimaraj, MD ARCHER Steering Committee
Wai Hong Wilson Tang, MD
Wai Hong Wilson Tang, MD ARCHER Steering Committee
Peter Liu, MD
Peter Liu, MD ARCHER Steering Committee
Carsten Tschöpe, MD
Carsten Tschöpe, MD ARCHER Steering Committee
Matthias Friedrich, MD
Matthias Friedrich, MD ARCHER Steering Committee
Edimar Bocchi, MD
Edimar Bocchi, MD ARCHER Steering Committee
Yaron Arbel, MD
Yaron Arbel, MD ARCHER Steering Committee
Mathieu Kerneis, MD, PhD
Mathieu Kerneis, MD, PhD ARCHER Steering Committee

Company History

Cardiol was incorporated on January 19, 2017, and on December 20, 2018, the Corporation completed its initial public offering on the Toronto Stock Exchange. As a result, the Common Shares commenced trading on the TSX under the symbol “CRDL”. On August 10, 2021, the Corporation’s Common Shares commenced trading on the Nasdaq Capital Market under the symbol “CRDL”.

Key International Research and Clinical Collaborators

We collaborate with world class researchers and clinicians at international centers of excellence and leverage their expertise in drug development, experimental execution, inflammation and fibrosis, the treatment of cardiovascular diseases, and clinical trial protocol design. Our collaborations provide the optimal advice and knowledge platform as we pursue our purpose: heal the heart with innovative science.